 LEIDEN, Netherlands CAMBRIDGE, Mass., April 23, 2021 GLOBE NEWSWIRE -- ProQR Therapeutics N.V. Nasdaq:PRQR, a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual oral presentation of data from the Companys Phase 12 InSight extension trial of sepofarsen and live QA session at the Association for Research in Vision and Ophthalmology ARVO held May 1-7, 2021. This is an encore presentation of the InSight study data that was presented during the Expert Perspectives Call in July 2020 . We expect to present new data from the InSight study in H2 2021. 